246 related articles for article (PubMed ID: 9598838)
1. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
Mohammadi A; Macri J; Newton R; Romain T; Dulay D; Adeli K
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):783-93. PubMed ID: 9598838
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Wilcox LJ; Barrett PH; Huff MW
J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
[TBL] [Abstract][Full Text] [Related]
3. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
Taghibiglou C; Van Iderstine SC; Kulinski A; Rudy D; Adeli K
Biochem Pharmacol; 2002 Feb; 63(3):349-60. PubMed ID: 11853686
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol esters regulate apoB48 secretion in CaCo2 cells.
Pal S; Allister E; Thomson A; Mamo JC
Atherosclerosis; 2002 Mar; 161(1):55-63. PubMed ID: 11882317
[TBL] [Abstract][Full Text] [Related]
6. Effects of tocotrienol on the intracellular translocation and degradation of apolipoprotein B: possible involvement of a proteasome independent pathway.
Wang Q; Theriault A; Gapor A; Adeli K
Biochem Biophys Res Commun; 1998 May; 246(3):640-3. PubMed ID: 9618265
[TBL] [Abstract][Full Text] [Related]
7. Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes.
Taghibiglou C; Rudy D; Van Iderstine SC; Aiton A; Cavallo D; Cheung R; Adeli K
J Lipid Res; 2000 Apr; 41(4):499-513. PubMed ID: 10744770
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters.
Borradaile NM; de Dreu LE; Barrett PH; Huff MW
J Lipid Res; 2002 Sep; 43(9):1544-54. PubMed ID: 12235187
[TBL] [Abstract][Full Text] [Related]
9. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.
Funatsu T; Suzuki K; Goto M; Arai Y; Kakuta H; Tanaka H; Yasuda S; Ida M; Nishijima S; Miyata K
Atherosclerosis; 2001 Jul; 157(1):107-15. PubMed ID: 11427209
[TBL] [Abstract][Full Text] [Related]
10. Effects of gamma-tocotrienol on ApoB synthesis, degradation, and secretion in HepG2 cells.
Theriault A; Wang Q; Gapor A; Adeli K
Arterioscler Thromb Vasc Biol; 1999 Mar; 19(3):704-12. PubMed ID: 10073977
[TBL] [Abstract][Full Text] [Related]
11. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin.
Borradaile NM; Carroll KK; Kurowska EM
Lipids; 1999 Jun; 34(6):591-8. PubMed ID: 10405973
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
Bisgaier CL; Essenburg AD; Auerbach BJ; Pape ME; Sekerke CS; Gee A; Wölle S; Newton RS
J Lipid Res; 1997 Dec; 38(12):2502-15. PubMed ID: 9458274
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.
Pau E; He Y; Lougheed M; Steinbrecher UP
Biochem Cell Biol; 1995; 73(1-2):81-90. PubMed ID: 7662319
[TBL] [Abstract][Full Text] [Related]
14. Studies of the sites of intracellular degradation of apolipoprotein B in Hep G2 cells.
Furukawa S; Sakata N; Ginsberg HN; Dixon JL
J Biol Chem; 1992 Nov; 267(31):22630-8. PubMed ID: 1429611
[TBL] [Abstract][Full Text] [Related]
15. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of biphasic effects of docosahexaenoic acid on apolipoprotein B secretion in HepG2 cells.
Wu X; Shang A; Jiang H; Ginsberg HN
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3347-55. PubMed ID: 9409332
[TBL] [Abstract][Full Text] [Related]
17. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
18. Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum.
Higashi Y; Itabe H; Fukase H; Mori M; Fujimoto Y; Takano T
J Biol Chem; 2003 Jun; 278(24):21450-8. PubMed ID: 12670935
[TBL] [Abstract][Full Text] [Related]
19. Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid.
Theriault A; Wang Q; Van Iderstine SC; Chen B; Franke AA; Adeli K
J Lipid Res; 2000 Dec; 41(12):1969-79. PubMed ID: 11108730
[TBL] [Abstract][Full Text] [Related]
20. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
